Seroba Life Sciences

Seroba FundIV final closed at EUR123M, announcedFebruary1,2024. The manager identifies five investments made since first close: Perfuze, Sibylla Biotech, Deciphex, Complement Therapeutics and Artica Therapeutics. The fund backs early-stage biotechnology and medical technology predominantly in Western Europe and selectively NorthAmerica. The EUR123M is actualfinalfundcapital, not the fundraising target or company-level allocation.

Historical first Seroba fund identified by Enterprise Ireland as Seroba BioVentures (Irish BioScience Venture Capital Fund), with EUR20M reported fund size. Exact close day unpublished; historical fund name is distinct from the current legal management company. This is fund capital, not a new company investment or current manager AUM.

Historical Seroba second life-sciences fund, identified in Enterprise Ireland’s2024 scheme report with a rounded EUR75M fund size. Older publications use Seroba Kernel Life Sciences FundII terminology. Exact final close day and full adviser-entity continuity are not inferred; current Seroba brand history is preserved without merging Kernel Capital itself.

Seroba’s third life-sciences fund. Its issuer’s February2,2017 announcement, reproduced by institutionalLP ISIF, confirms an actual EUR100M first close. Enterprise Ireland’s2024 fund directory later reports corpusEUR101.02M. The latest reported size is recorded; unknown final close date is NULL rather than attaching the later size to the earlier firstclose day. No fund capital is automatically attributed to company cash allocations.